Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
This publication addresses the growing importance of precision medicine in breast cancer diagnosis and treatment in China, highlighting the shift from traditional histological classification to molecular-based approaches.
It emphasizes the rapid development of molecular biology techniques and the increasing role of molecular pathological testing in enabling individualized treatment strategies.
The article discusses key challenges, including:
- Standardization
- Quality control
- The need for unified diagnostic and treatment pathways
It introduces the “Guidelines on clinical practice of molecular tests in breast cancer in China (2025 edition)”, formulated through multidisciplinary collaboration and evidence-based evaluation.
These guidelines aim to:
- Integrate international advancements with local clinical realities
- Optimize molecular testing algorithms
- Support hereditary risk assessment and prognostic stratification
- Promote multidisciplinary cooperation
Overall, the guidelines seek to improve precision oncology and contribute to China’s public health goals.